Sanofi
A global biopharmaceutical company that discovers, develops, and markets medicines and vaccines.
SAN | PA
Overview
Corporate Details
- ISIN(s):
- FR0000120578 (+39 more)
- LEI:
- 549300E9PC51EN656011
- Country:
- France
- Address:
- 46 AVENUE DE LA GRANDE ARMEE, 75017 PARIS
- Sector:
- Manufacturing
Description
Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2023-01-31 19:03 |
6-K
|
English | ZIP • 66.6 KB | ||
| 2023-01-30 18:15 |
Sanofi: Disclosure of trading in own shares
|
English | PDF • 2.6 MB | ||
| 2023-01-30 18:15 |
Sanofi : Déclaration des transactions sur actions propres
|
French | PDF • 1.7 MB | ||
| 2023-01-30 07:00 |
Communiqué de presse: Dupixent® (dupilumab), premier et seul médicament ciblé a…
|
French | PDF • 217.3 KB | ||
| 2023-01-30 07:00 |
Press Release: Dupixent® (dupilumab) approved by European Commission as the fi…
|
English | PDF • 215.8 KB | ||
| 2023-01-27 07:00 |
Communiqué de presse: Le CHMP recommande l’extension des indications de Dupixen…
|
French | PDF • 177.3 KB | ||
| 2023-01-27 07:00 |
Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by th…
|
English | PDF • 175.1 KB | ||
| 2023-01-25 23:30 |
Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demon…
|
English | PDF • 208.6 KB | ||
| 2023-01-25 23:30 |
Communiqué de presse : Le NEJM publie des données de phase III sur l’efanesocto…
|
French | PDF • 221.9 KB | ||
| 2023-01-23 18:15 |
Sanofi : Déclaration des transactions sur actions propres
|
English | PDF • 1.6 MB | ||
| 2023-01-23 18:15 |
Sanofi: Disclosure of trading in own shares
|
English | PDF • 2.4 MB | ||
| 2023-01-17 20:44 |
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Decem…
|
French | PDF • 118.6 KB | ||
| 2023-01-17 20:44 |
Sanofi: Information concerning the total number of voting rights and shares – D…
|
English | PDF • 142.4 KB | ||
| 2023-01-17 20:27 |
Sanofi: Disclosure of trading in own shares
|
English | PDF • 2.7 MB | ||
| 2023-01-17 20:27 |
Sanofi : Déclaration des transactions sur actions propres
|
French | PDF • 1.9 MB |
Automate Your Workflow. Get a real-time feed of all Sanofi filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sanofi
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sanofi via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-02 | N/A | Other | Buy | 71,423 | N/A |
| 2024-04-26 | N/A | Other | Buy | 1,000 | 91,380.00 EUR |
| 2023-06-09 | N/A | Other | Buy | 9 | 856.04 EUR |
| 2023-05-02 | N/A | Other | Buy | 65,205 | 6,364,008.00 EUR |
| 2023-05-02 | N/A | Other | Buy | 500 | 48,835.00 EUR |
Peer Companies
